Scholarlink

<p>There is great promise for the focused therapeutic use of microballoons, a new gastro-retentive drug delivery device. Drug bioavailability is improved, and localized action is ensured in the stomach due to their buoyant qualities, which allow for prolonged gastric stay. This technology shines in <i>Helicobacter pylori</i> infection because the gastric mucosa is specifically targeted by microballoons, which would enable sustained drug delivery. In addition, microballoons have been developed to encapsulate multiple medications, showcasing their adaptability in treating a wide range of ailments, such as cancer, gastrointestinal infections, and metabolic disorders. Stable, hollow microballoons require precise control of temperature, stirring speed, solvent system, polymer type and concentration, and other formulation factors. Inconsistent cavity development may affect medication loading and buoyancy. Literature was retrieved from PubMed, Scopus, and Google Scholar and appraised for design quality and bias. Microballoons demonstrate prolonged gastric residence and controlled release, improving local drug bioavailability and reducing systemic side effects. However, methodological heterogeneity, small sample sizes, and the absence of standardized in vitro/in vivo evaluation restrict cross-study comparison and clinical translation. The paper delves into the floating property of microballoons and their potential to treat <i>H. pylori</i> infection and accompanying ulcers, sophisticated characterization techniques, varied formulations customized for individual therapeutic needs, and more. The review also covers their stability and effectiveness, as well as their buoyancy, drug release patterns, and stomach retention characteristics, all of which can be evaluated with precision thanks to contemporary technology. Offering a regulated, continuous-release platform that maximizes therapeutic benefits while minimizing systemic side effects, this innovative approach marks a paradigm shift in drug delivery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An Innovative Approach for the Elimination of Helicobacter pylori: Floating Microballoons for the Prolonged Delivery of Antibiotics

  • 期刊论文

  • 发表日期：

    2026年2月4日

查看全文
  • Prakash Goudanavar

摘要

There is great promise for the focused therapeutic use of microballoons, a new gastro-retentive drug delivery device. Drug bioavailability is improved, and localized action is ensured in the stomach due to their buoyant qualities, which allow for prolonged gastric stay. This technology shines in Helicobacter pylori infection because the gastric mucosa is specifically targeted by microballoons, which would enable sustained drug delivery. In addition, microballoons have been developed to encapsulate multiple medications, showcasing their adaptability in treating a wide range of ailments, such as cancer, gastrointestinal infections, and metabolic disorders. Stable, hollow microballoons require precise control of temperature, stirring speed, solvent system, polymer type and concentration, and other formulation factors. Inconsistent cavity development may affect medication loading and buoyancy. Literature was retrieved from PubMed, Scopus, and Google Scholar and appraised for design quality and bias. Microballoons demonstrate prolonged gastric residence and controlled release, improving local drug bioavailability and reducing systemic side effects. However, methodological heterogeneity, small sample sizes, and the absence of standardized in vitro/in vivo evaluation restrict cross-study comparison and clinical translation. The paper delves into the floating property of microballoons and their potential to treat H. pylori infection and accompanying ulcers, sophisticated characterization techniques, varied formulations customized for individual therapeutic needs, and more. The review also covers their stability and effectiveness, as well as their buoyancy, drug release patterns, and stomach retention characteristics, all of which can be evaluated with precision thanks to contemporary technology. Offering a regulated, continuous-release platform that maximizes therapeutic benefits while minimizing systemic side effects, this innovative approach marks a paradigm shift in drug delivery.